Achieve Life Sciences (NASDAQ:ACHV - Get Free Report)'s stock had its "outperform" rating reaffirmed by Oppenheimer in a note issued to investors on Monday, Benzinga reports. They currently have a $18.00 price target on the biopharmaceutical company's stock. Oppenheimer's price target suggests a potential upside of 293.01% from the company's current price.
Separately, Lake Street Capital lowered their price target on Achieve Life Sciences from $19.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, March 5th.
Read Our Latest Analysis on ACHV
Achieve Life Sciences Trading Up 0.8 %
Shares of ACHV traded up $0.04 during trading hours on Monday, hitting $4.58. The stock had a trading volume of 127,509 shares, compared to its average volume of 93,249. The company has a debt-to-equity ratio of 4.02, a quick ratio of 5.36 and a current ratio of 5.36. The firm has a market cap of $96.96 million, a P/E ratio of -2.99 and a beta of 1.32. The company's fifty day simple moving average is $4.50 and its 200 day simple moving average is $4.40. Achieve Life Sciences has a 12-month low of $3.03 and a 12-month high of $10.30.
Institutional Trading of Achieve Life Sciences
Several large investors have recently modified their holdings of ACHV. Raymond James & Associates acquired a new stake in shares of Achieve Life Sciences during the first quarter valued at about $99,000. Charles Schwab Investment Management Inc. bought a new position in shares of Achieve Life Sciences during the first quarter worth about $79,000. State Street Corp lifted its position in shares of Achieve Life Sciences by 26.9% during the first quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company's stock worth $142,000 after purchasing an additional 3,970 shares during the last quarter. LPL Financial LLC lifted its position in shares of Achieve Life Sciences by 17.5% during the second quarter. LPL Financial LLC now owns 101,700 shares of the biopharmaceutical company's stock worth $496,000 after purchasing an additional 15,150 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Achieve Life Sciences by 57.5% during the second quarter. Renaissance Technologies LLC now owns 39,700 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 14,500 shares during the last quarter. 33.52% of the stock is currently owned by institutional investors and hedge funds.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Recommended Stories
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
